Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tore Saxne

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
BMC Musculoskeletal Disorders|December 13, 2006
Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritisMaria L E Andersson, Carina A Thorstensson, Ewa M Roos, et al.
Annals of the Rheumatic Diseases|August 24, 2011
National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patientsJohan A Karlsson, Jan-Åke Nilsson, Martin Neovius, et al.
Annals of the Rheumatic Diseases|December 13, 2006
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritisLennart T H Jacobsson, Carl Turesson, Jan-Ake Nilsson, et al.
Rheumatology (Oxford, England)|May 14, 2011
Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort studyLars E Kristensen, Ingemar F Petersson, Pierre Geborek, et al.
The Journal of Biological Chemistry|June 12, 2014
Novel cartilage oligomeric matrix protein (COMP) neoepitopes identified in synovial fluids from patients with joint diseases using affinity chromatography and mass spectrometryEmma Åhrman, Pilar Lorenzo, Kristin Holmgren, et al.
The Journal of Rheumatology|July 5, 2005
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritisLennart T H Jacobsson, Carl Turesson, Anders Gülfe, et al.
Annals of the Rheumatic Diseases|August 10, 2010
Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort studyTor Olofsson, Martin Englund, Tore Saxne, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2017
Activation of Complement by Pigment Epithelium-Derived Factor in Rheumatoid ArthritisLeonie M Vogt, Simone Talens, Ewa Kwasniewicz, et al.
BMC Musculoskeletal Disorders|August 7, 2013
Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritisMaria L E Andersson, Björn Svensson, Ingemar F Petersson, et al.
Acta Paediatrica (Oslo, Norway : 1992)|December 29, 2015
Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritisRobin Kahn, Elisabet Berthold, Birgitta Gullstrand, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
BMC Musculoskeletal Disorders|December 13, 2006
Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritisMaria L E Andersson, Carina A Thorstensson, Ewa M Roos, et al.
Annals of the Rheumatic Diseases|August 24, 2011
National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patientsJohan A Karlsson, Jan-Åke Nilsson, Martin Neovius, et al.
Annals of the Rheumatic Diseases|December 13, 2006
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritisLennart T H Jacobsson, Carl Turesson, Jan-Ake Nilsson, et al.
Rheumatology (Oxford, England)|May 14, 2011
Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort studyLars E Kristensen, Ingemar F Petersson, Pierre Geborek, et al.
The Journal of Biological Chemistry|June 12, 2014
Novel cartilage oligomeric matrix protein (COMP) neoepitopes identified in synovial fluids from patients with joint diseases using affinity chromatography and mass spectrometryEmma Åhrman, Pilar Lorenzo, Kristin Holmgren, et al.
The Journal of Rheumatology|July 5, 2005
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritisLennart T H Jacobsson, Carl Turesson, Anders Gülfe, et al.
Annals of the Rheumatic Diseases|August 10, 2010
Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort studyTor Olofsson, Martin Englund, Tore Saxne, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2017
Activation of Complement by Pigment Epithelium-Derived Factor in Rheumatoid ArthritisLeonie M Vogt, Simone Talens, Ewa Kwasniewicz, et al.
BMC Musculoskeletal Disorders|August 7, 2013
Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritisMaria L E Andersson, Björn Svensson, Ingemar F Petersson, et al.
Acta Paediatrica (Oslo, Norway : 1992)|December 29, 2015
Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritisRobin Kahn, Elisabet Berthold, Birgitta Gullstrand, et al.
Pageof 9